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Abstract
Background:  Defined daily doses remain as the most objective factor and can be considered as the cornerstone for making decision on determining 
the needs and organization of rational use of medicines, as well as for providing in practices suggestion of WHO Global Strategy that defines the use of 
antimicrobials in hospital treatment of patients.
Material and methods:  For this study we used data of 2009-2014 period, in the Emergency Medicine Institute of the Republic of Moldova which shows 
the dynamics of consumption of medicinal remedies of pharmaco-therapeutic group J – Antibacterials for systemic use of the Anatomical Therapeutical 
Chemical World Health Organization’s classification. 
Results:  Total annual consumption of drugs group J – Antibacterials for systemic use in the evaluated period records a decrease from 662.2 DDD/1000 in 
2009 to 464.1 in 2014 or by 29.9%, of which for parenteral use from 568.9 in 2009 to 346.9 or by 39% and for oral use from 93.28 to 117.20 or an increase 
by 25.6%.  From total concumption the ratio between parenteral and oral use in the evaluated period varied from 85.9/14.1 to 74.8/25.2 percentage. 
Conclusions:  The obtained data reveals that consumption of drugs group J – Antibacterials for systemic use in the evaluated period decreased significantly 
and in 2014 recorded a mean consumption of European hospitals.
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Introduction
We can find more international, regional and national 
programs [1-8] aimed to survey the usage of antibiotics, 
involving dozens of countries which have thousands of hos-
pitals and other public health institutions. The article aims at 
collating and evaluating data on antimicrobial or antibacte-
rials (antibiotics) usage in the Emergency Medicine Institute 
over a certain time, enabling  monitoring of trends in use of 
this group of drugs based on the Anatomical Therapeutical 
Chemical (ATC) World Health Organization’s (WHO) clas-
sification system standards. Present research covers antibi-
otics utilization data, as a rate based on defined daily doses, 
enables reporting and comparison of total-hospital usage for 
the period from January 2009 to January 2014.  This report 
provides data which could be used to target particular areas 
of antibiotics’ usage.  At the hospital level the usage trends is 
a parameter for identifying overall changes in anti-infective 
treatment practices.
Emergency Medicine Institute of the Republic of Moldova 
(EMI), was founded in 1959.  Clinical Services of EMI inclu-
de: Orthopedic-Traumatology Clinic for 150 beds, Surgery 
Clinic for 140 beds, Neurosurgery Clinic for 80 beds, Neu-
rology Clinic for 70 beds, Maxillo-facial clinic for 30 beds, 
Urology Clinic for 40 beds, Gynecology Clinic for 30 beds, 
Microsurgery Clinic for 30 beds, Municipal Center with 8 
seats hemodialysis and 9 beds, Clinical intensive care units 
(CICU) for 30 beds, in total the above clinical services of the 
institution include 600 beds, also are included 5 emergency 
medical help substations and 4 out-patient departments of 
traumatology and orthopedics [9].
The primary aim of the study was to evaluate institutional 
representative data on antibiotics utilization for a period of 
six years (2009-2014), according to WHO requirements to 
determine the  value of defined daily doses (DDD) per 1000 
occupied-bed days (OBD) and compare these data with the 
results of the use of antibiotics in hospitals from other coun-
tries.  Based on obtained data it aimed to make conclusions 
on the consumption of antibiotics in hospitals for ensuring 
the optimization of planning needs and their rational use.
To determine DDD and compare the consumption of 
antibiotics for the period of 2009-2014, the statistics data 
concerning the number of treated patients, the number of 
occupied bed/days and total annual quantities of antibiotics 
were used.  The total number of occupied bed/days in the 
institution was 188762 in 2009, 191556 in 2010, 186246 in 
2011, 199816 in 2012, 193019 in 2013 and 187558 in 2014 
[10, 11, 12].
Antimicrobial data are aggregated over the time period of 
interest at hospital level and converted to standardized usage 
route based on the WHO definition of DDD with 1000 OBD 
as the denominator [13, 14, 15].
Material and methods
For this study we used data on a six-year (2009-2014) 
period in EMI, which show the dynamics of consumption of 
medicinal remedies of pharmaco-therapeutic group J – An-
tibacterials for systemic use, as classified ATC, classification 
system of World Health Organization indicating the nature 
value.  Statistical, analytical, mathematical, comparative, lo-
gical and descriptive methods of study were used.
Results and discussion
To determine DDD and compare the consumption of 
antibiotics for the period of 2009-2014, the statistics data 
concerning the number of treated patients (only patients with 
health insurance and other free treated by the state categories 
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of citizens), the number of occupied bed/days and total annual 
quantities of medicines were used.
In figure 1 are demonstrated the total (parenteral and oral 
forms) antibiotic groups use rates of DDD/1000 OBD in EMI. 
The average aggregate annual rate for total-hospital antibiotics 
utilization period decreased from 662.4 DDD/1000 OBD in 
2009 to 464.1 DDD/1000 OBD in 2014, or by 29, 9%. Near 
every group of antibiotics is shown the usage rate for 2014 
and the yearly trends for the evaluation period in comparison 
with 2009.
Annual usage rate data, aggregated by year and therape-
utic group, for six years from January 2009 to January 2014, 
demonstrated the increase in usage rates for tetracyclines by 
253.7% (from 8.2 to 20.8 DDD/1000), amphenicols by 160% 
(from 0.5 to 0.8 DDD/1000), other beta-lactam antibiotics by 
100.7% (from 270.8 to 272.6 DDD/1000) and antimycotics 
for systemic use by 178.5% (from 12.1 to 21.6 DDD/1000). 
A decline in usage rates was recorded for beta-lactam anti-
biotics, penicillin by 75.6% (from 85.5 to 20.8 DDD/1000), 
sulfonamides and trimethoprim by 100% (from 5.7 to 0 
DDD/1000), macrolides and lincosamides by 96,6% (from 
44.4 to 1.5 DDD/1000), aminoglycoside antibiotics by 47.4% 
(from 83.1 to 43.7 DDD/1000), quinolone antibiotics  by 49.2% 
(from 91.0 to 46.2 DDD/1000) and other antibiotics by 40.9% 
(from 61.1 to 36.1 DDD/1000).
In figure 2 are presented trends of usage rates DDD/1000 
OBD of antibiotic groups (parenteral forms) in EMI.  The 
average consumption annual rate in the evaluation period 
recorded a decline from 568.9 DDD/1000 OBD in 2009 to 
346.9 DDD/1000 OBD in 2014 or by 39%. Near every grupe 
of antibiotics is showen usage rate for 2014 and the yearly 
trends for the evaluation period in comparison with 2009.
During the evaluated period was registered an increased 
usage of amphenicols by 160% (from 0.5 to 0.8 DDD/1000) 
and antimycotics for systemic usage by 180% (from 0.5 to 0.9 
DDD/1000). A decline in usage rates was recorded for beta-
lactam antibiotics by 95.1% (from 79.9 to 3.9 DDD/1000), 
other beta-lactam antibiotics by 7.9% (from 268.5 to 247.3 
DDD/1000), macrolides, lincosamides and streptogramins 
by 98% (from 43.7 to 0.9 DDD/1000), aminoglycoside for 
systemic by 47.4% (from 83.1 to 43.7 DDD/1000), quinolone 
antibiotics by 65.7% (from 41.7 to 14.3 DDD/1000) and other 
antibiotics by 31% (from 50.9 to 35.1 DDD/1000). 
In figure 3 are presented trends in groups of antibiotics 
for oral use in EMI in the evaluation period.  The average 
consumption annual rate of antibiotics for oral usage increa-
sed from 93.28 DDD/1000 OBD in 2009 to 117.2 DDD/1000 
OBD in 2014 or by 125.7%.  Near every group of antibiotics 
is shown usage rate for 2014 and the yearly trends for the 
evaluation period in comparison with 2009.
  As we can see from fig. 3 in the consumption of oral 
forms of antibiotics in the evaluated period was registered an 
increased usage for tetracyclines by 253.7% (from 8.2 to 20.8 
DDD/1000), beta-lactam antibiotics by 301.8% (from 5.6 to 
16.9 DDD/1000), other beta-lactam antibiotics by 11.5 times 
(from 2.2 to 25.3 DDD/1000) and antimycotics for systemic 
use by 180% (from 11.5 to 20.7 DDD/1000). A decline in 
Fig. 1.  Total antibiotics usage rates DDD/1000 OBD  
in 2009-2014 (parenteral and oral forms).
Fig. 2.  Total antibiotics usage rates DDD/1000 OBD  
in 2009-2014 (parenteral forms).
Fig. 3.  Total antibiotics usage rates DDD/1000 OBD 
 in 2009-2014 (oral usage).
usage rates was recorded for sulfonamides and trimetoprim 
by 100% (from 5.0 to 0 DDD/1000), macrolides, lincosamides 
and streptogramins by 14.2% (from 0.7 to 0.6 DDD/1000), 
quinolone antibiotics by 35.2% (from 49.2 to 31.9 DDD/1000), 
other antibiotics by 90.1% (from 10.1 to 1.0 DDD/1000).  The 
annual trends of consumption of antibiotics for parenteral and 
oral use are presented in table 1.
From the data presented in table 1 we can state that the 
usage trends of antibiotics for parenteral and oral use during 
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the evaluated period, recorded for parenteral use a decline 
by 11.1 % (85.9% - 74.8%), and for oral use respectively an 
increase by the same 11.1% (25.2%-14.1%).
The percentage usage trends of DDD/1000 OBD per day of 
antibiotics group J – Antibacterials (ATC J01) for systemic use 
of the EMI of Republic of Moldova and other seven countries 
from the European Union, such as: Bulgaria, Ireland, Estonia, 
Lithuania, Latvia, Sweden and Finland are presented in table 2.
Utilizing the DDD/1000 OBD per day data [15, 16], we 
have calculated the percentage usage trends for the large 
antibiotics groups ATC J01 of the EMI and seven countries 
from European Union.  The results demonstrate that the 
average proportion of consumption in seven countries from 
Table 1
Trends of antibiotics for parenteral and oral usage in NSPCEM in 2009-2014
Route/years 2009 2010 2011 2012 2013 2014
TOTAL parenteral 568.9 85.9% 471.6 84.5% 521.5 78.7% 460.1 84.8% 441.9 80.8% 346.9 74.8%
TOTAL oral 93.28 14.1% 86.6 15.5% 100.6 21.3% 82.25 15.2% 105.0 19.2% 117.2 25.2%
TOTAL 662.2 100% 558.2 84.3% 622.1 93.9% 542.4 81.9% 546.9  82.6% 464.1  70.1%
Table 2
Percentage usage trends of DDD/1000 OBD per day of antibiotics group ATC J01  
between the EMI of the Republic of Moldova and seven European courtiers 
Country/
Antibacterial groups EMI of RM Bulgaria Ireland Estonia Lithuania Latvia Sweden Finland
Tetracyclines 4.37 1.42 1.12 4.44 2.5 3.0 12.01 7.5
Beta-lactam Penicilins 4.48 20.0 9.44 32.77 24.16 30.33 50.66 18.57
Other Beta-lactam antibiotics 58.74 51.44 49.44 26.11 22. 37.66 13.33 32.5
Macrolides Lincosamides and 
streptogramins 0.32 7.85 14.44 10.55 2.5 4.33 4.0 5.35
Quinolone antibiotics 9.95 7.85 7.77 10.55 6.25 11.66 10.66 12.14
Other antibiotics 7.78 14.28 14.44 14.15 40.41 10.66 7.33 20.71
European Union and EMI are for tetracyclines 4.37:4.6, beta-
lactam antibiotics 26.6:4.48, other beta- antibiotics 58.47:33.3, 
macrolides, lincosamides and streptogramins 7:0.32, 
quinolone antibiotics 9.6:9.95, other antibiotics 15.4:7.78. 
In table 3 is presented total-hospital usage rates of 
DDD/1000 OBD of antimicrobials between the EMI and ten 
international researches with the data from more than 2000 
hospitals of European countries.
The results show that in ten international researches [4, 20, 
21, 22, 23, 24] the medium minimal consumption of DDD/1000 
is 433.77 and medium maximal – 499.31 units.  So, recorded con-
sumption in EMI of 464.1 DDD/1000 units of antibiotics in 2014 
in comparison with the presented below results is intermediate.
Table 3
Comparison of total-hospital usage rates of DDD/1000 OBD  
of antibiotics between the EMI and ten international researches
Hospitals DDD/1000 % consumption 
EMI of the Republic of Moldova 464.1 464.1 = 100%
34 public/43 private hospitals in France [17] 395 - 422 85.11% - 90.93%
Antibiotic use in 530 French hospitals [18] 62.3 - 557.7 13.42%-120.17%
University Hospital of Geneva [19] 400 86.62%
Besancon University Hospital in France [20] 535.4 115.36%
74 south-western French hospitals [21] 400 - 450 86.19% - 96.96%
University Medical Center Rotterdam
The Netherlands [22] 547 117.86%
1115 hospitals in France [23] 370 - 393 79.72% - 84.68%
University Hospital Huddinge, Sweden [24] 430 92.65%
139 hospitals from 30 European countries [25] 496 106.87%
All hospitals in Netherlands [4] 702 151.26%
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Conclusions
1. The average aggregate annual rate for total-institutional 
antibiotics utilization decreased from 662.4 in 2009 to 464.1 
DDD/1000 OBD in 2014, or by 29. 9%. Of which a significant 
decline in usage rates was recorded for beta-lactam antibiotics, 
penicillin by 75.6% (from 85.5 to 20.8 DDD/1000), macrolides 
and lincosamides by 96.6% (from 44.4 to 1.5 DDD/1000), 
aminoglycoside antibiotics by 47.4% (from 83.1 to 43.7 
DDD/1000), quinolone antibiotics  by 49.2% (from 91.0 to 
46.2 DDD/1000) and other antibiotics by 40.9% (from 61.1 to 
36.1 DDD/1000). At the same time an increase in usage rates 
was recorded for tetracyclines by 253.7% (from 8.2 to 20.8 
DDD/1000) and antimycotics for systemic useg by 178.5% 
(from 12.1 to 21.6 DDD/1000).
2. For parenteral form of use the consumption annual 
rate in the evaluation period recorded a decline from 568.9 
DDD/1000 OBD in 2009 to 346.9 DDD/1000 OBD in 2014 
or by 39%. Of which a significant decline in usage rates was 
recorded for beta-lactam antibiotics by 95.1% (from 79.9 to 3.9 
DDD/1000) lincosamides and streptogramins by 98% (from 
43.7 to 0.9 DDD/1000), aminoglycoside for systemic use by 
47.4% (from 83.1 to 43.7 DDD/1000), quinolone antibiotics 
by 65.7% (from 41.7 to 14.3 DDD/1000) and other antibiotics 
by 31% (from 50.9 to 35.1 DDD/1000).
3. For oral form of use the consumption annual rate re-
corded an increase from 93.28 DDD/1000 OBD in 2009 to 
117.2 DDD/1000 OBD in 2014 or by 125.7%, of which  more 
significantly for tetracyclines by 253.7% (from 8.2 to 20.8 
DDD/1000), beta-lactam antibiotics by 301.8% (from 5.6 to 
16.9 DDD/1000), other beta-lactam antibiotics by 11.5 times 
(from 2.2 to 25.3 DDD/1000) and antimycotics for systemic 
use by 180% (from 11.5 to 20.7 DDD/1000). At the same time 
a decline in usage rates was recorded for sulfonamides and 
trimetoprim by 100% (from 5.0 to 0 DDD/1000), quinolone 
antibiotics by 35.2% (from 49.2 to 31.9 DDD/1000) and other 
antibiotics by 90.1% (from 10.1 to 1.0 DDD/1000). 
4. The average proportions of consumption of main groups 
of antibiotics in seven countries from the European Union 
and EMI are for tetracyclines 4.37:4.6, beta-lactam antibiotics 
26.6:4.48, other beta- antibiotics 58.47:33.3, macrolides, lin-
cosamides and streptogramins 7:0.32, quinolone antibiotics 
9.6:9.95, other antibiotics 15.4:7.78. 
5. The recorded consumption of 464.1 DDD/1000 units 
of antibiotics in EMI in 2014 in comparison with medium 
minimal consumption of 433.77 and medium maximal of 
499.31 units of DDD/1000 from ten international researches is 
intermediate. This is a result of six years efforts for rational use 
of antibiotics since 2009 when consumption of antimicrobials 
DDD/1000 in EMI was 662.2 units or by 132.7% more than 
medium maximal in European countries.
6. One of the most evident results of the present research 
is a clear demonstration that today implementation of DDD 
program consumption study of antibiotics in all hospitals 
of health system of the Republic of Moldova is indubitable 
necessity for qualitative determination of annual planning of 
necessary drugs and their rational use organization. 
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